A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)

• Status: Completed
• Trial end date: 2012-11-08
• Target enrollment: 0
• Participant gender: Male

Summary

This multiple dose study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)- infected participants. The primary hypothesis is that administration of grazoprevir for 7 days is sufficiently safe and well tolerated in HCV-infected males.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Grazoprevir

Criteria

Inclusion Criteria:

• Baseline health is stable.

• Has a clinical diagnosis of chronic HCV infection.

Exclusion Criteria:

• Has a history of stroke or chronic seizures.

• Has a history of cancer.

• Has a history of human immunodeficiency virus (HIV) infection.

• Has had major surgery, donated blood or participated in another investigational study within the past 3 months.